N/A N=80 Supraventricular Tachycardia Collection Study
Supraventricular Arrhythmias
Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=59 Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias
Premature Atrial Contraction
Primary: Change in Premature Atrial Contractions (PACs) — -0.6; -5.6 Episodes/hour
N/A N=85 Dipole Density Mapping in Supraventricular Tachycardia
Supraventricular Tachycardia
Primary: Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events — 71; 14; 85; 83 Participants
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
Phase 2 N=69 ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
Atrial Fibrillation
Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001
N/A N=31 Characterising the Stable and Dynamic Left Atrial Substrate in Atrial Fibrillation
Atrial Fibrillation
Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV
N/A N=157 AVAI: Atrial Ventricular Arrythmia Incidence
Ventricular Tachycardia · Atrial Fibrillation
Primary: Slow Ventricular Tachycardia Episodes Devices Detected (Between 120-150 Bpm and > 30sec) Atrial Fibrillation (AF) Episodes Devices Detected (> 30 Sec) — 3778; 112; 68…
N/A N=20 Imaging With a Radio Tracer to Guide VT Ablations
Ventricular Tachycardia · Arrhythmia
Primary: Comparison of the Percentage of Patients With Scar in Each Segment as Determined by MIBG SPECT Versus Electroanatomic at Baseline — 2; 4; 1; 4 Participants
N/A N=180 Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial
Ventricular Tachycardia (VT)
Primary: Freedom From Recurrent VT, Cardiovascular Rehospitalization, and All-cause Mortality — 33; 25; 28; 27 Participants
N/A N=74 Using Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia
Supraventricular Tachycardia
Primary: Total Fluoroscopy Time — 18.3; 7.5 minutes
N/A N=110 A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
Atrial Fibrillation
Primary: Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse…
Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants
N/A N=234 Dysrhythmias During General Anesthesia in Children
Arrhythmias, Cardiac
Primary: Arrhythmias During General Anesthesia in Children — 220 participants
Phase 4 N=246 DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
Ventricular Tachycardia · Premature Ventricular Contraction · Stroke
Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001
N/A N=53 Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation
Atrial Fibrillation · Inflammation
Primary: Atrial Fibrillation Burden — 2; 8.5 Percent time spent in atrial fibrillatio
Phase 4 N=16 Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
Tachycardia, Ventricular
Primary: Inhibition of Idiopathic Ventricular Tachycardia
Phase 2 N=199 Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
Paroxysmal Supraventricular Tachycardia (PSVT)
Primary: The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration — 20; 15; 20; 13 Participants — p=<0.05
Phase 3 N=72 Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia
Supraventricular Tachycardia
Primary: Incidence of Recurrent Supraventricular Tachycardia (SVT) Requiring Medical Intervention to Terminate the Episode. — 12; 18 percentage of participants
Phase 4 N=67 Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study
Permanent Atrial Fibrillation
Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001
N/A N=35 Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial
Atrial Fibrillation · Arrhythmias, Cardiac
Primary: Recurrence Rate of Atrial Arrhythmias — 8; 14; 7; 1 participants — p=0.047
N/A N=1 Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
Refractory Ventricular Tachycardia
Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants
N/A N=498 Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmias
Cardiac Arrhythmia · Atrial Fibrillation
Primary: Compare the Diagnostic Performance of Physician Rhythm Interpretation of 1-lead ECG Generated by SkyLabs CART-I Ring and Apple Watch Versus 12-lead ECG (Gold-standard)…
Phase 3 N=127 First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)
Atrial Fibrillation
Primary: Number of Participants With Recurrence of Atrial Tachyarrhythmia — 36; 44 Participants — p=0.0016
N/A N=321 Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation
Heart Failure · Recurrent Atrial Fibrillation
Primary: All Hospital Episodes (Emergency Room or Patient Request for OPD) Related to Treatment for Atrial Arrhythmia — 19; 76; 23 Participants — p=<0.0001
Phase 2 N=22 Pilot Randomized Trial With Flecainide in ARVC Patients
Arrhythmogenic Right Ventricular Cardiomyopathy
Primary: Number of Ventricular Ectopic Beats (VEBs) Per Day — 2685; 677 number of VEBs per day — p=<0.0001
Phase 2 N=19 Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia
Ventricular Tachycardia · Cardiomyopathy · Premature Ventricular Contractions
Primary: Number of Serious Adverse Events — 2; 0; 0; 1 Events
Phase 4 N=1,902 Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III
Heart Disease
Primary: For the Primary Endpoint the Reduction of Ventricular Therapies (ATP and Shocks) Delivered for Treating Fast Spontaneous Arrhythmia Episodes Was Measured. — 67.1; 41.9…
Phase 3 N=458 Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)
Atrial Fibrillation
Primary: Postoperative Atrial Fibrillation — 27.2; 27.8; 25.9 percentage of patients — p=0.95
Phase 3 N=26 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Change in Heart Rate — 17.0; 13.1 beats per minute
N/A N=149 A Study For Treatment Of Paroxysmal Atrial Fibrillation (PAF) With The THERMOCOOL SMARTTOUCH SF Catheter and TRUPULSE Generator
Atrial Fibrillation
Primary: Percentage of Participants With Primary Adverse Events (PAEs) — 0.0; 0.0; 1.5; 1.5 percentage of participants